These 3 Pharma Stocks Could Be Your Best 10x Trade of November 2025

I'm always looking for high-potential pharma stocks. This sector is tough. You're not usually looking for 10x gains in the big, stable companies. The real explosive potential... the kind that can multiply your investment... is often in smaller clinical-stage biotechs.

These companies can succeed or fail based on one single event. It could be a clinical trial result or an FDA approval. This makes them very high risk, and I've been doing a lot of homework.

It turns out this month, November 2025, is critical for a few companies. I'm sharing what I've found.

I've found two companies that are facing their "make or break" moment this month. These are called PDUFA dates. It's the FDA's deadline to approve or reject their new drug.

First is Arrowhead Pharmaceuticals (ARWR). They work on "gene silencing" drugs. They have an FDA decision date on November 18, 2025, for their drug Plozasiran. This drug treats a rare genetic disease, and if approved, it's a huge deal for them.

Second is Kura Oncology (KURA). They make targeted cancer drugs. Their big FDA date is November 30, 2025, for Ziftomenib, a drug for a specific type of leukemia.

These are what I call "binary events." The stocks could gap up significantly on an approval or fall hard on a rejection. It's the definition of high-risk, high-reward.

When you're tracking events this specific, you can't just casually check the price. You need the right tools. I'm using TradingView for this, and it's essential for my research.

Here’s my exact, simple process in TradingView:

1. Set Up the Chart: I open the chart for KURA or ARWR.
2. Draw Price Levels: I look at the chart and draw horizontal lines at recent support (the price it bounces off of) and resistance (the price it struggles to break through).
3. Set Alerts: This is the most important step. I set alerts above the resistance line and below the support line. I’ll get an instant notification on my phone if the price breaks out in either direction, which will almost certainly happen when the news drops.
4. Add the Date: I use the "Text" tool right on the chart to write "PDUFA: Nov 18" on ARWR and "PDUFA: Nov 30" on KURA. This way, I can't possibly forget the catalyst date when I'm looking at the chart.

This setup takes me two minutes, and it means I don't have to watch the screen all day. If you want to get serious about tracking your own ideas, you need a tool like this. You can sign up and try it yourself at /tradingview.

📚 Recommended Resources

10x Stock Checklist: My 47-point System

6 Simple Steps Spotting Undervalued Stocks

Earn $500/Month with Dividend Stocks

3 Swing Trading Strategies for Predictable Gains

Besides the November gambles, I'm watching Viking Therapeutics (VKTX).

This company is a key player in the obesity drug race. They are trying to develop their own drugs to compete with the big guys.

There isn't a single FDA date for them this month, but their big catalyst is happening right now. They are presenting the detailed data from their "VENTURE" study at the ObesityWeek conference (which runs from Nov 4-7). This is where we get the full details on their drug's performance. The stock will react to how good (or bad) that data is compared to its competitors.

This is a longer-term story, but this week's data is a major milestone. I'm using the /tradingview-screener to compare VKTX against its competitors on technical metrics, not just news.

If you're trying to figure out how to even begin analyzing a biotech stock like this, it can be overwhelming. I put together all my own criteria into a simple checklist. You can download it here: 10x Stock Checklist: My Exact 47-Point Analysis Framework. It's what I use to make sure I don't miss anything.

Finally, I'm looking at Pfizer (PFE). This is a completely different kind of idea. It is not a 10x lottery ticket. This is a "recovery" play.

The stock is down a lot. Its huge revenue from COVID vaccines has disappeared, and investors are wondering what's next.

The new story for Pfizer is cancer drugs. They spent $43 billion to buy Seagen. This was a huge bet to become a leader in oncology. I just looked at their Q3 2025 earnings report, and it looks like the plan is starting to work.

Here are the key metrics: Their total revenue was down, but their non-COVID products grew 4% operationally, and the specific Oncology unit also grew 4%. On top of that, they raised their full-year 2025 profit (EPS) guidance.

This suggests the company is cheap and the worst might be over. It's a bet that the market is wrong about Pfizer's future.

My main takeaway... do your own homework. My 47-Point Checklist is a good place to start.

Disclaimer: This is just my personal research and thought process. This is not financial advice. These stocks are high-risk, and you must do your own research.